Código QR

Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States

Michele Jara, Thomas Aquilina, Peter Aupperle, Adrian L Rabinowicz Acorda Therapeutics, Inc., Ardsley, NY, USA Background: Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine outside the US), 10 mg twice daily, was approved by the US Food...

Descrición completa

Gardado en:
Principais autores: Jara M, Aquilina T, Aupperle P, Rabinowicz AL
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2015-12-01
Series:Drug, Healthcare and Patient Safety
Assuntos:
dalfampridine
fampridine
multiple sclerosis
adverse events
postmarketing safety
Acceso en liña:https://www.dovepress.com/safety-profile-of-dalfampridine-extended-release-in-multiple-sclerosis-peer-reviewed-article-DHPS
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares